Voruciclib poly morphs and methods of making and using thereof
TW202038945A
Combination therapy
WO2020112848A1
Combination therapies for high and very high risk mds
WO2020036999A1
Treatment of b cell malignancies
AU2019322858A1
Combination therapy
AU2019321526A1
Treatment of relapsed follicular lymphoma
CA3093847A1
Combination therapy
SG11202001258UA
Combination therapy
WO2018217787A1
Combination therapy
KR20190058550A
Combination therapy
CN109414425A
The polymorphic forms and application thereof of 3- [2- butyl -1- (2- Diethylamino-ethyl) -1H- benzimidazole -5- base]-N- hydroxy-acrylamide
CN107427003A
Therapeutic alliance
EP3662911A1
Combination of azacitidine and pracinostat to treat myelodysplastic syndrome (mds)
WO2014055647A1
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
IL228599D0
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US2014161908A1
Chroman derivatives, medicaments and use in therapy
SG193984A1
(alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
NZ615960A
(alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
EP2691388A1
(fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
EP2635273A2
Isoflavonoid compositions and methods for the treatment of cancer
